New Appature system zeros in on customer behavior

Share this article:
Bob Harrell
Bob Harrell

A CME matrix can be ponderous. Agency whiteboards are filled with possibilities, including how many audiences, how many messages, and how often each target should be contacted. The ideal is that readers interact with every bit of content that makes it into their inboxes. The drawback: a significant amount of waiting to see how much readers engage with the messaging or when they shut down and tune out.

Bob Harrell, IMS Health-Appature's director of marketing says its cloud-based system Journeys, which launched in August, shows how customers are behaving in real time and provides what amounts to a heat map that shows where people are clicking within the email itself as well as where they are interacting within the outlined communication stream.

Harrell says Journeys gives agencies or their clients a real-time accounting of who is in the communication stream and how they are behaving. Second, it lets marketers add new messages or even branches to the communications matrix, providing more opportunities to engage readers.

He says the ease of use is along the lines of programming in the Apple interface vs. MSDOS, freeing up marketers from needing a tech-heavy component to keep campaigns moving.

At the same time, he says the program's cloud setup helps marketers make a quick pivot and halt a communications stream to respond to a regulatory event; the whiteboard equivalent of erasing a dead end.

Harrell says the immediate audience is a mid-tier pharma company. Appature is promoting Journeys at conferences.
Share this article:

Email Newsletters

More in Features

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...